There are many aminoglycoside antibiotics derived from actinomyces bacteria, including streptomycin, gentamicin, and tobramycin. These antibiotics have sugar rings derived from glucose and similar biosynthetic pathways, though one bacteria can produce varying molecules. While recombinant DNA techniques have generated novel structures, none have proven superior to existing drugs. Large-scale fermentations for aminoglycoside production commonly use soy products and release nutrients slowly to prevent feedback inhibition of antibiotic synthesis.
There are many aminoglycoside antibiotics derived from actinomyces bacteria, including streptomycin, gentamicin, and tobramycin. These antibiotics have sugar rings derived from glucose and similar biosynthetic pathways, though one bacteria can produce varying molecules. While recombinant DNA techniques have generated novel structures, none have proven superior to existing drugs. Large-scale fermentations for aminoglycoside production commonly use soy products and release nutrients slowly to prevent feedback inhibition of antibiotic synthesis.
There are many aminoglycoside antibiotics derived from actinomyces bacteria, including streptomycin, gentamicin, and tobramycin. These antibiotics have sugar rings derived from glucose and similar biosynthetic pathways, though one bacteria can produce varying molecules. While recombinant DNA techniques have generated novel structures, none have proven superior to existing drugs. Large-scale fermentations for aminoglycoside production commonly use soy products and release nutrients slowly to prevent feedback inhibition of antibiotic synthesis.
There are many aminoglycosides in medical use and are all derived from actinomyces spp.
For example; streptomycin (S. griseus), gentamicin (Micromonospora purpurea), tobramycin
(S. teriebrarius), kanamycin (S. kanamyceticus). sisomicin (M. inyoesis). Some have been modified chemically to produce derivatives with resistance to clinical isolates with acquired resistance to earlier aminoglycoside types. Of particular interest is the use of the hydroxy-γ- aminobutyryl side chain to give anti-pseudomonal activity to amikacin. This side chain occurs naturally in the aminoglycoside butirosin produced by Bacillus circulans. Netilmicin is chemically derived from sisomisin. Bacterial resistance occurs by enzymatic modification, e.g. acylation, phosphorylation or adenylation of the various amine and hydroxyl groups. All ring structures of these antibiotics are derived from glucose, synthesised separately and then assembled into the final molecule. Most of the biosynthetic enzymes and their associated genes have been identified. Many similarities in biosynthesis have been seen across the wide variety of aminoglycosides. In addition one culture can produce a variety of molecules e.g. kanamycin A, B, C or gentamicin C1, C2, C1a, C2a. Recombinant DNA techniques have been used to produce hybrid aminoglycosides (Mutasynthesis), and many novel structures have been produced. However, none has been found to be superior to existing structures. Strain improvement programmes have been successful in increasing fermentation titres to 15-20 mg ml-1. Additional challenges have been to either reduce the production or unwanted products e.g. kanamycin C, or maintain the required ratios, e.g. gentamicin C1, C2, C1a.
Large-scale fermentations of aminoglycosides have several similar features. Use of soy
products is common, e.g. soy flour or soy meal. Antibiotic synthesis is sensitive to feedback repression by glucose, ammonia and phosphate. For these reasons ammonium and phosphate salts are not used in the starting batch. Nitrogen is obtained from the slow metabolism of the soy proteins and the necessary phosphate is obtained from organic sources such as physic acid. Starch is commonly used in the starting batch as streptomyces have poor amylase activities and the release of glucose is slow and rate limiting. Alternatively, corn syrups can be fed at predetermined rates.